MSH6与PMS2突变与监测发现的结直肠癌风险关联
新西兰前瞻性队列研究纳入381例Lynch综合征患者,定期结肠镜监测。MSH6突变者70岁累积结直肠癌风险为8.5%,显著低于MLH1突变者(HR 0.2)。33%监测发现的结直肠癌可能源于腺瘤性息肉切除不完整。
要点
- MSH6突变者结直肠癌风险显著低于MLH1突变者(HR 0.2)。
- 监测发现的结直肠癌94%为0-II期,无癌相关死亡。
- 33%监测发现的结直肠癌可能与息肉切除不完整有关。
核心结论
- MSH6或PMS2突变者结直肠癌风险显著低于MLH1突变者。
- 不完整腺瘤性息肉切除可能导致三分之一的监测发现结直肠癌。
研究设计与样本
- 前瞻性国家队列研究,纳入新西兰381例Lynch综合征患者(MLH1 98例、MSH2 159例、MSH6 103例、PMS2 21例)。
- 参与者从25岁起每年接受结肠镜检查,最终分析纳入至少2次结肠镜检查者,排除既往结肠切除、结直肠癌史或指数结肠镜确诊结直肠癌者。
主要发现
- 共进行2061次结肠镜检查,随访2296人年,中位观察期4.43年,入组平均年龄43岁。
- 中位随访6.5年(范围1-16年)期间18例发生结直肠癌(MLH1 8例、MSH2 8例、MSH6 2例)。
- 首次监测结肠镜后5年总体结直肠癌风险为2.49%(95%CI 1.18-5.23)。
关键数值与推荐
- MSH6突变者70岁累积结直肠癌风险为8.5%。
- 首次监测结肠镜后5年结直肠癌总体风险为2.49%(95%CI 1.18-5.23)。
临床怎么用
- 对于MSH6或PMS2突变者,可考虑较MLH1突变者降低监测强度,但需个体化。
- 监测结肠镜时应注意确保腺瘤性息肉完整切除,以降低间期结直肠癌风险。
局限性
- 样本量有限,尤其PMS2突变者仅21例。
- 中位随访时间较短(4.43年),长期风险需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Lynch syndrome is the most common inherited cause of colorectal cancer (CRC). Contemporary and mutation-specific estimates of CRC-risk in patients undergoing colonoscopy would optimize surveillance strategies. We performed a prospective national cohort study, using data from New Zealand, to assess overall and mutation-specific risk of CRC in patients with Lynch syndrome undergoing surveillance. METHODS: We performed a prospective study of 381 persons with Lynch syndrome in New Zealand (98 with Lynch-syndrome associated variants in MLH1, 159 in MSH2, 103 in MSH6, and 21 in PMS2). Participants were offered annual colonoscopy starting at age 25 y, and those who underwent 2 or more colonoscopies before December 31, 2017 were included in the final analysis. Patients with previous colonic resection, history of CRC or diagnosis of CRC at index colonoscopy were excluded. RESULTS: Study participants underwent 2061 colonoscopies during 2296 person-y; the median observation-period was 4.43 y and mean-age at enrollment was 43 y. Eighteen patients developed CRC (8 with variants in MLH1, 8 in MSH2, and 2 in MSH6) after a median follow-up period of 6.5 y (range 1-16 y). Eighty-three percent of patients had a surveillance colonoscopy in preceding 24 months before diagnosis of CRC; 94% were diagnosed with stage 0-II CRC and there was no CRC-related mortality. The overall-risk of developing CRC in the 5 y after first surveillance colonoscopy was 2.49% (95% CI, 1.18-5.23); cumulative risks for CRC in patients with Lynch syndrome-associated variants in MLH1, MSH2, or MSH6 by age 70 y were 17.7%, 17.8%, and 8.5%, respectively. Age-adjusted CRC-risk in patients with variants in MSH6 was lower than in MLH1 (hazard ratio, 0.2; 95% CI, 0.04-0.94; P = .02). Of patients with CRC, 33% had an adenomatous polyp resected from same segment in which a colorectal tumor later developed. CONCLUSIONS: The risk of CRC in patients with Lynch syndrome-associated mutations in MSH6 or PMS2 was significantly lower than in patients with mutations in MLH1. Incomplete adenomatous polyp resection might be responsible for one third of surveillance-detected CRCs.
引用
- Lamba M, Wakeman C, Ebel R, et al. Associations Between Mutations in MSH6 and PMS2 and Risk of Surveillance-detected Colorectal Cancer. Clin Gastroenterol Hepatol. 2020. PMID: 32240831. doi:10.1016/j.cgh.2020.03.048
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。